Clinical Trials Directory

Trials / Terminated

TerminatedNCT01148160

Voriconazole Trough Plasma Levels : Genetic Polymorphism, Efficacy, Safety in Patients With Hematologic Malignancy

The Correlation of Voriconazole Trough Plasma Levels With Genetic Polymorphism, Efficacy, and Safety Outcomes in Hematologic Malignancy Patients With Invasive Pulmonary Aspergillosis

Status
Terminated
Phase
Study type
Observational
Enrollment
10 (actual)
Sponsor
Asan Medical Center · Academic / Other
Sex
All
Age
15 Years
Healthy volunteers
Not accepted

Summary

Multiple factors are associated with a large variability in voriconazole exposure following standard dose administration, such as non-linear saturable pharmacokinetics, drug-drug interactions, liver disease, patient age, and genetic polymorphism of the metabolic enzymes. Voriconazole is extensively metabolized by the human hepatic enzymes, primarily mediated by CYP2C19. The polymorphisms account for a relatively large portion of inter-individual variance observed in voriconazole plasma concentrations. However, there are limited data on the relationships between voriconazole blood levels and clinical outcomes or safety in Asian populations. The purpose of this study is to investigate the relationships of voriconazole blood levels with genetic polymorphism, safety, and clinical outcomes in immunocompromised patients with invasive pulmonary aspergillosis.

Detailed description

The investigators are trying to establish that routine clinical practice for voriconazole therapeutic drug monitoring can improve the efficacy and safety outcomes. In Korean patients with hematologic malignancy, the investigators also want to propose the optimal dosing guideline of voriconazole with different genetic polymorphisms.

Conditions

Interventions

TypeNameDescription
DRUGvoriconazoleintravenous, oral administration

Timeline

Start date
2010-08-01
Primary completion
2014-04-01
Completion
2014-04-01
First posted
2010-06-22
Last updated
2014-04-10

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT01148160. Inclusion in this directory is not an endorsement.